188 related articles for article (PubMed ID: 28156019)
1. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.
Malecic N; Young HS
Exp Dermatol; 2017 Apr; 26(4):299-304. PubMed ID: 28156019
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis.
Luengas-Martinez A; Hardman-Smart J; Paus R; Young HS
Exp Dermatol; 2020 Aug; 29(8):687-698. PubMed ID: 32654325
[TBL] [Abstract][Full Text] [Related]
3. Targeting VEGF/VEGFR in the treatment of psoriasis.
Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis.
Armstrong AW; Voyles SV; Armstrong EJ; Fuller EN; Rutledge JC
J Dermatol Sci; 2011 Jul; 63(1):1-9. PubMed ID: 21600738
[TBL] [Abstract][Full Text] [Related]
5. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis.
Henno A; Blacher S; Lambert CA; Deroanne C; Noël A; Lapière C; de la Brassinne M; Nusgens BV; Colige A
J Dermatol Sci; 2010 Mar; 57(3):162-9. PubMed ID: 20071151
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
7. The role of angiogenesis in the pathogenesis of psoriasis.
Chua RA; Arbiser JL
Autoimmunity; 2009 Nov; 42(7):574-9. PubMed ID: 19863376
[TBL] [Abstract][Full Text] [Related]
8. Investigational VEGF antagonists for psoriasis.
Crawshaw AA; Griffiths CE; Young HS
Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed fibulin-3 contributes to the pathogenesis of psoriasis by promoting angiogenesis.
Wang X; Sun X; Qu X; Li C; Yang P; Jia J; Liu J; Zheng Y
Clin Exp Dermatol; 2019 Jun; 44(4):e64-e72. PubMed ID: 30146751
[TBL] [Abstract][Full Text] [Related]
10. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.
Malecic N; Young HS
Expert Opin Investig Drugs; 2016; 25(4):455-62. PubMed ID: 26864055
[TBL] [Abstract][Full Text] [Related]
11. Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?
Capkin AA; Demir S; Mentese A; Bulut Ç; Ayar A
Arch Dermatol Res; 2017 Apr; 309(3):203-207. PubMed ID: 28238185
[TBL] [Abstract][Full Text] [Related]
12. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model.
Ren X; Li J; Zhou X; Luo X; Huang N; Wang Y; Chen X; Wei Y
Dermatology; 2009; 219(3):232-8. PubMed ID: 19729876
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis.
Midde HS; Priyadarssini M; Rajappa M; Munisamy M; Mohan Raj PS; Singh S; Priyadarshini G
Clin Exp Dermatol; 2021 Jan; 46(1):50-57. PubMed ID: 32516443
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
Nofal A; Al-Makhzangy I; Attwa E; Nassar A; Abdalmoati A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):803-6. PubMed ID: 19309427
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of hypoxia-inducible factors in normal and psoriatic skin.
Rosenberger C; Solovan C; Rosenberger AD; Jinping L; Treudler R; Frei U; Eckardt KU; Brown LF
J Invest Dermatol; 2007 Oct; 127(10):2445-52. PubMed ID: 17495954
[TBL] [Abstract][Full Text] [Related]
17. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis.
Shahidi-Dadras M; Haghighatkhah HR; Abdollahimajd F; Younespour S; Partovi Kia M; Zargari O
Int J Dermatol; 2016 Jan; 55(1):52-9. PubMed ID: 26135969
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in Chronic Inflammatory Skin Disorders.
Lee HJ; Hong YJ; Kim M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769465
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis.
Henno A; Blacher S; Lambert C; Colige A; Seidel L; Noël A; Lapière C; de la Brassinne M; Nusgens BV
Br J Dermatol; 2009 Mar; 160(3):581-90. PubMed ID: 18945297
[TBL] [Abstract][Full Text] [Related]
20. Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice.
Canavese M; Altruda F; Silengo L; Castiglioni V; Scanziani E; Radaelli E
Histol Histopathol; 2011 Mar; 26(3):285-96. PubMed ID: 21210341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
